Navigation Links
NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus-like Particle (VLP) Vaccine Candidate
Date:9/1/2009

aw with our VLP vaccine candidate as compared with the egg-based vaccine, we are now particularly excited to begin the larger head-to-head study in elderly adults this Fall," Dr. Heaton said.

The results of this study are strongly supportive of accelerated development of Novavax's pandemic influenza vaccines, including the novel H1N1 2009 influenza VLP vaccine. "We are working tirelessly with partners and governments worldwide to potentially provide H1N1 vaccine to regions without an indigenous supply," said Dr. Rahul Singhvi, President and Chief Executive Officer of Novavax. "The current influenza pandemic underscores the potential for Novavax's advanced influenza vaccine technology to have significant public health impact by providing vaccine in time to those in need," said Dr. Singhvi.

Seasonal and Pandemic Influenza

Seasonal epidemics of influenza cause an estimated 200,000 hospitalizations and 36,000 deaths in the US each year. With the H1N1 2009 influenza pandemic, US health officials are projecting an additional 30,000 to 90,000 deaths will occur during the upcoming influenza season and approximately 40% of US citizens will be infected. Because the H1N1 2009 virus is a new strain, individuals lack antibody to fight it. Good handwashing, coughing into a sleeve, and staying home when ill are some ways to prevent H1N1 flu; however, the most effective way to prevent it is through vaccination.

Globally, seasonal flu infects between 5 percent and 20 percent of the population and kills between 250,000 and 500,000 people each year. Because of the limited number of individuals with antibody against the novel H1N1 2009 virus, the World Health Organization (WHO) has projected that up to a third of the world's population may be infected this year, with as many as 15% of those requiring hospital care.

About Novavax

Novavax is a clinical-stage biotechnology
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. NOVAVAX Virus-Like Particle Vaccine Protects Against 2009 Pandemic H1N1 Influenza Virus
2. Novavax Reports Second Quarter 2009 Financial Results
3. Novavax Announces Appointment of Frederick W. Driscoll as Vice President, Chief Financial Officer and Treasurer
4. Novavax Announces Release Date of 2009 Second Quarter, Financial Results and Investor Conference Call
5. Novavax Announces Selection of a Respiratory Syncytial Virus Vaccine Candidate for Advanced Preclinical Studies
6. Novavax Announces Appointment of John J. Trizzino as Senior Vice President, International and Government Alliances
7. Novavax Announces Repayment of $5 Million of Convertible Debt
8. Cadila Pharmaceuticals Launches Joint Venture With Novavax in India
9. Spanish Government Selects Novavaxs VLP Technology for Comprehensive Flu Vaccine Solution in Spain
10. Novavax Appoints Stanley Erck to Board of Directors
11. Preclinical Proof-of-Concept Studies Published for Novavax Seasonal Influenza Virus-Like-Particle Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... June 30, 2015  The University of California, ... (CCE/Bio) and UC San Diego Extension announced their ... held Aug.  12 – 14, 2015, at UC ... workshop provides an intense exposure to best practices ... is well-suited to biologists, process engineers and business ...
(Date:6/30/2015)... June 30, 2015  The Dr. Samadi Prostate Cancer Center ... offering a full suite of new genetic testing methods for ... for diagnosing prostate cancer. Dr. Samadi,s ... tests for assessing the risk and optimizing the diagnosis of ... very excited to now offer these revolutionary genetic tests to ...
(Date:6/30/2015)... ... June 30, 2015 , ... Cannavoices , Inc., a ... digital video and broadcast initiative. Produced by filmmakers, the multi-platform initiative aims to ... medical cannabis stories ever assembled. , Cannavoices profiles Advocates, Patients, Entrepreneurs, Growers, ...
(Date:6/29/2015)... Manhattan, KS (PRWEB) , ... June 29, 2015 ... ... US PATENT 7736892 B2. Under the terms of the agreement, MediVet will acquire ... Matrix Stem Cells (UCMSCs). MB-007 is currently in pre-clinical development as a potential ...
Breaking Biology Technology:UC San Diego Extension to Offer Third Annual Microbial Fermentation Workshop 2New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 2New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 3New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 4New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 5Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 2Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 3MediVet Biologics Acquires Exclusive Patent License from Kansas State University 2MediVet Biologics Acquires Exclusive Patent License from Kansas State University 3
... BOSTON, March 12 Vical Incorporated (Nasdaq:,VICL) announced ... of its,product development programs on Monday, March 17, ... Conference (Boston -- March 17-20)., About Vical, ... on its,patented DNA delivery technologies for the prevention ...
... 11:00 a.m. ET; 8:00 a.m. PT, VANCOUVER and ... OTC: MGIFF), a clinical-stage developer of drugs for infectious,diseases, ... March 13,2008 at 11:00 a.m. ET (8:00 a.m. PT) ... January 31, 2008 and provide an update on,company activities. ...
... (Nasdaq: IDEV ) today announced the Company will ... Care Conference, on,Tuesday, March 18, 2008 at 1:40 pm ... presentation will be web cast live and may be,accessed ... at, http://www.indevus.com ., About Indevus, Indevus Pharmaceuticals, ...
Cached Biology Technology:Vical to Present at Cowen and Company Health Care Conference 2Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference 2Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference 3
(Date:6/17/2015)... HILDEN , Deutschland und GERMANTOWN, Maryland ... Investigator ®   Produktlinie mit ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime ... neue STR-Testkits der Produktlinie Investigator ... DNA-Spuren in den Markt eingeführt. Die neuen Kits zur ...
(Date:6/16/2015)... /CNW Telbec/ - handyem Inc. and FlowMetric Diagnostics ... of handyem,s HPC-150 portable flow cytometer within FlowMetric ... unprecedented model of mobile laboratory platform is presented ... Pennsylvania Convention Center, ... to 18 th 2015.  By virtue of ...
(Date:6/15/2015)... -- According to a new market research ... and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image ... The Natural Language Processing Market is expected to grow ... the forecast period 2015-2020. Browse 65 ... spread   through 155 P ages and in-depth ...
Breaking Biology News(10 mins):QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3Natural Language Processing Market Worth $13.4 Billion by 2020 2Natural Language Processing Market Worth $13.4 Billion by 2020 3Natural Language Processing Market Worth $13.4 Billion by 2020 4Natural Language Processing Market Worth $13.4 Billion by 2020 5
... protein that regulates gene expression may play a role in ... psychiatric disease. As reported in the latest issue of ... Bipolar Disorders, levels of SP4 (specificity protein 4) were lower ... from patients with bipolar disorder. The study suggests that normalization ...
... DST Health Solutions , LLC, today announced ... (CCHP) has implemented its PowerMHC® core claims administration platform ... new market requirements and enhance data integration. In addition, ... line service for CCHP, which supports more than 31,000 ...
... of a cellular mechanism linked to the toxicity of ... study, published in Environmental Science & Technology , ... neurological diseases such as Alzheimer,s. "I,m not implying ... Michael Plewa, lead scientist and professor of genetics in ...
Cached Biology News:Gene regulatory protein is reduced in bipolar disorder 2Gene regulatory protein is reduced in bipolar disorder 3DST Health Solutions' Integrated Care Management Suite Improves Care Quality, Population Management of 31,000+ Member Health Plan 2DST Health Solutions' Integrated Care Management Suite Improves Care Quality, Population Management of 31,000+ Member Health Plan 3Research links water disinfection byproducts to adverse health effects 2Research links water disinfection byproducts to adverse health effects 3
BD IMag Anti-Mouse CD90.2 (Thy1.2) Particles-DM 2 x 109 cells...
...
...
... Ribonuclease III (RNase III) from E. ... double-stranded RNA (dsRNA) to dsRNA fragments that ... dsRNA results in dsRNA fragments of 12-15 ... RNA composed of canonical ribonucleotides as well ...
Biology Products: